AAV

Adenovirus
#AAV #Cell and gene therapy #Gene delivery #Gene therapy #Roundtable

Guide to using AAV vectors in gene therapy

In 2023, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. The event aimed to help the audience understand the AAV workflow, from upstream methods for AAV production and validation to downstream analysis of the packaged product for… Read More

#Exclusive Content

#AAV #Biotech #Drug discovery #Flow Cytometry #Life sciences

Biotechs to compete in Dragon’s Den session at BioProcessUK 

Life sciences companies are set to compete in a Dragon’s Den session at the BIA’s BioProcessUK event this month.   Taking place on day two of BIA BioProcess UK, the Dragon’s Den special session is focused on next generation analytical technologies and will see six companies compete for… Read More

#News

#AAV #AskBio #Duchenne muscular dystrophy #Gene editing #Giant axonal neuropathy #Haemophilia #Pompe disease

Podcast: The evolution and future of gene therapy

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dr… Read More

#News

Adenovirus
#AAV #Azenta Life Sciences #Gene delivery #Gene therapy #Webinar

Guide to using AAV vectors in gene therapy

Earlier this year, DDW hosted a webinar, 'A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy', supported by Azenta Life Sciences. The event aimed to help the audience understand the AAV workflow, from upstream methods for AAV production and validation to downstream analysis of the packaged product… Read More

#Exclusive Content

Heart monitor
#AAV #Cardiovascular disease #Collaboration #Evox Therapeutics #Gene therapy #Icahn School of Medicine

Research partners advance AAV gene therapy for heart disease

Evox Therapeutics has agreed a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY, US. The collaboration will work on developing exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology aimed at improving… Read More

#News

Gene therapy
#AAV #Azenta Life Sciences #Drug development #Drug discovery #Gene therapy #Webinar

Learn how to use adeno-associated virus (AAV) vectors in gene therapy

Join DDW for this exclusive free event, A Comprehensive Guide to Using Adeno-Associated Virus (AAV) Vectors in Gene Therapy, which is supported by Azenta Life Sciences.  AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV… Read More

#News

Approval stamp
#AAV #Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Gene therapy #Genetics / genomics #Muscular dystrophy #Sarepta Therapeutics

FDA approves first gene therapy for Duchenne muscular dystrophy

Sarepta Therapeutics’ Elevidys has become the first gene therapy for Duchenne muscular dystrophy (DMD) to gain marketing authorisation in the US. The Food and Drug Administration (FDA) has granted accelerated approval to Elevidys (delandistrogene moxeparvovec-rokl), an adeno-associated virus (AAV) based gene therapy for the treatment of DMD. It is approved… Read More

#News #Regulatory #Trending News

AAV
#AAV #Azenta Life Sciences #Drug development #Drug discovery #Gene therapy #Webinar

A guide to using adeno-associated virus (AAV) vectors in gene therapy

Join DDW for this exclusive free event, A Comprehensive Guide to Using Adeno-Associated Virus (AAV) Vectors in Gene Therapy, which is supported by Azenta Life Sciences.  AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV… Read More

#News

Exosomes
#AAV #Codiak Biosciences #Evox Therapeutics #Mergers and acquisitions #Preclinical development

Evox Therapeutics acquires exosome AAV technology from Codiak

Evox Therapeutics has purchased Codiak Biosciences engEx-AAV technology platform, including all intellectual property rights, and exclusive access to certain engineering and manufacturing rights. The technology enables active loading of adeno-associated virus (AAV) into exosomes followed by their release when the AAV-loaded exosomes are delivered into recipient cells. This has been… Read More

#Business & Investment #News

AAV
#AAV #Azenta Life Sciences #Drug development #Drug discovery #Gene therapy #Plasmid DNA

A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy

AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers. In this webinar, supported by Azenta Life Sciences, we’ll help you understand the AAV workflow, from upstream methods for AAV production and validation to downstream analysis of the… Read More

Webinar date:
Brought to you by Azenta Life Sciences
#Webinars

VectorBuilder Edinburgh office
#AAV #Biotech hubs #Expansion #Gene delivery #UK #VectorBuilder

Viral vector provider opens new UK headquarters in Edinburgh

Gene delivery technologies company VectorBuilder has opened a new office in Edinburgh, hoping to bolster its presence in the United Kingdom. The new location is part of Edinburgh Technopole, a Pioneer Group in Midlothian Science Zone. “When it comes to published scientific research, the UK is… Read More

#News

Neurons
#AAV #Genetics / genomics #High throughput screening #Neuroscience #Sania Therapeutics #University College London

Start-up will focus on medicines for neural circuit dysfunction

Sania Therapeutics, a new company focused on developing genetic medicines for neural circuit dysfunction, has launched at the American Society of Gene & Cell Therapy (ASGCT) conference. The company’s approach combines adeno-associated viruses (AAV) in human neural circuits with tuneable conditionally-activated ion channels. This corrects dysfunctional neural excitation. Sania’s technology… Read More

#Business & Investment #News

Start-up hopes to boost production of viral vectors for ATMPs
#AAV #Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Seed funding #Start-ups

Start-up hopes to boost production of viral vectors for ATMPs

New South African company NewBiologix has launched with the aim of developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies. The company’s DNA-based platform is being developed to address manufacturing challenges associated with the production… Read More

#News #Start-up Zone

Gene therapy
#AAV #EMA #Gene therapy #Genethon #Genetic diseases #Liver disease #Priority Review

Gene therapy for rare liver disease gets EMA priority status

The European Medicines Agency (EMA) has granted PRIME (Priority Medicines) status to the gene therapy, GNT-0003, currently in clinical trials for Crigler-Najjar syndrome, a rare liver disease.   This status, granted only to drug candidates with major therapeutic potential, follows the successful completion of the first phases of the clinical trials. … Read More

#Editor's Choice #News #Regulatory

#AAV #Cell and gene therapy #Drug development #Drug discovery #Gene therapy #Immunology / Virology & Vaccines

Optimising AAV capsid purification through improved analytics

Listen to this article on the DDW Podcast: Svea Cheeseman, Refeyn, explains why better efficiency is needed to advance the production of viral vectors for use in gene therapies. Adeno-associated viruses (AAVs) are a promising, widely used vector for delivering gene therapies. As demand for AAV gene therapies increases, it is… Read More

#Exclusive Content